This guide was put together using insights from individuals working directly on Pharma/CMO relationships. In each case we asked individuals how they would tackle a particular CMO crisis and have collated their insights into this handy guide. Example of a CMO crisis included in this guide is; How would you collect and react fast if a batch was rejected in order to keep the supply chain safe?
What you will discover from the presentation:
The crucial make or buy question, and the special challenges with outsourcing bio-manufacture
Best practices for successful CDO or CMO partnerships
Understanding and mitigating the risks, and analyse how you can protect your IP
The considerations for complex supply networks and fast track projects
We have put together a handbook of exclusive information on some of the most pertinent issues facing the sector. This handbooks draws on the discussions of leading experts and real-life experiences shared at the Pharma Contract Manufacturing conference, and will serve as a guide to navigating the challenges of Pharma/CMO relationships and best practises for building long-lasting strategic partnerships for the future.
Nowadays, nearly 80% of drugs currently FDA approved on behalf of small bio/pharma companies are contract manufactured, and 50% of products supported by mid-size companies use a CMO. In the lead up to the Pharma Contract Manufacturing Conference, Pharma IQ have looked at the evolution of the roles of CMOs and CDMOs in the industry, and what the future will bring for these organisations.